Search

Displaying results 1401 - 1410 of 10000 in total
  1. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.

  2. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD. … Infection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as

  3. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. … Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021.

  4. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [L64112] The European Commission granted marketing authorization on August 24, 2026 for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged 5 years and older

  5. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. … Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations.

    Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5ML
  6. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    accelerated approval based on reduction of proteinuria. … [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559]

    Categories: Agents Acting on the Renin-Angiotensin System
  7. Drug

    Hetacillin

    go.drugbank.com/drugs/DB00739
    ApprovedVet approvedWithdrawn

    The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. … Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria.

  8. Indication

    Bone Marrow Suppression caused by Chemotherapy

    go.drugbank.com/conditions/DBCOND0137031
    Drugs: Trilaciclib
    Synonyms: Bone Marrow Suppression caused by Chemotherapy
  9. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … [L10370] Butalbital‐containing analgesics can also produce a drug‐induced headache in addition to tolerance and dependence.

    Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acid
  10. Drug

    Varicella zoster vaccine (recombinant)

    go.drugbank.com/drugs/DB13924
    ApprovedInvestigational

    first line therapy[L1038]. … The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV).

    Synonyms: gE recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein E